Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Pharming Group N.V.NASDAQ: PHAR

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $6.64M fell 20.2% year over year, behind the +32.9% change in trailing-twelve-month cost of revenue. Sequentially, it fell 72.6% from the prior quarter. Over 3 fiscal years it compounded at +37.5% a year.

Context

  • Cost of revenue amounted to 12.1% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.2% toward the trailing-twelve-month pace of +32.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.64M-72.6% QoQ
Last fiscal yearDec 2025
$45.63M+24.5% YoY
LTMMar 2026
$46.97M+32.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.2%——
1 year+24.5%——
3-year CAGR+37.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
45.63M USD
Year-over-year change
+24.5%
4-year CAGR
+17.5%

Cost of Revenue vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +32.9% is the 5th highest of 8, against a peer median of +44.2%.
  • Cost of revenue amounts to 12.7% of revenue for PHAR, versus a peer median of 20.1%.
PHAR Competitors
Cost of Revenue for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$206.11B USD+35566.9%+13.6%20.1%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$719.42M USD+4201.4%+42.5%76.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$167.7M USD-26.7%+28.1%253.7%
PHARPharming Group N.V.LTM Mar 2026$46.97M USD+32.9%+37.5%12.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M USD+44.2%+4.3%1.8%
STOKStoke Therapeutics, Inc.LTM Mar 2026$3.09M USD+178.5%—9.6%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$2.15M USD-8.3%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
PHVSPharvaris N.V.LTM Sep 2026€106.45K EUR+9.7%——
Peer median (excluding PHAR) —+44.2%+13.6%20.1%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.